THE LUPUS LOW DISEASE ACTIVITY STATE (LLDAS) DEFINITION DISCRIMINATES RESPONDERS IN A SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) TRIAL: POST-HOC ANALYSIS OF THE PHASE IIB MUSE TRIAL OF ANIFROLUMAB

被引：1
|
作者：
Morand, E. [1 ]
Berglind, A. [2 ]
Sheytanova, T. [2 ]
Tummala, R. [2 ]
Illei, G. [3 ]
机构：
[1] Monash Univ, Melbourne, Vic, Australia
[2] AstraZeneca, Molndal, Sweden
[3] MedImmune LLC, Gaithersburg, MD USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2017年 / 76卷
关键词：
D O I：
10.1136/annrheumdis-2017-eular.2464
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
OP0001
引用
收藏
页码：50 / 50
页数：1
相关论文
共 50 条
  • [21] Predictors of Remission (on and off Treatment) and Lupus Low Disease Activity State (LLDAS) in Systemic Lupus Erythematosus (SLE): Data from a Multinational, Multicenter SLICC (Systemic Lupus International Collaborating Clinics) Cohort
    Ugarte-Gil, Manuel
    Ruiz-Irastorza, Guillermo
    Gladman, Dafna
    Urowitz, Murray
    Clarke, Ann
    Hanly, John
    Gordon, Caroline
    Bae, Sang-Cheol
    Romero-Diaz, Juanita
    Sanchez-Guerrero, Jorge
    Bernatsky, Sasha
    Wallace, Daniel
    Isenberg, David
    Rahman, Anisur
    Merrill, Joan
    Fortin, Paul R.
    Bruce, Ian N.
    Petri, Michelle
    Ginzler, Ellen
    Dooley, Mary Anne
    Ramsey-Goldman, Rosalind
    Manzi, Susan
    Jnsen, Andreas
    van Vollenhoven, Ronald F.
    Aranow, Cynthia
    Mackay, Meggan
    Lim, S. Sam
    Inanc, Murat
    Kalunian, Kenneth
    Jacobsen, Soren
    Peschken, Christine
    Kamen, Diane
    Askanase, Anca
    Pons-Estel, Bernardo A.
    Alarcn, Graciela
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 2639 - 2641
  • [22] Lupus Low Disease Activity State (LLDAS) Achievement with Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in a Phase 2 Trial in SLE
    Morand, Eric
    Hobar, Coburn
    Pomponi, Samantha
    Koti, Ravi
    Wegman, Thomas
    van Vollenhoven, Ronald
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 2961 - 2963
  • [23] Consensus Definition and Preliminary Validation Of a Low Disease Activity State In Systemic Lupus Erythematosus
    Morand, Eric F.
    Franklyn, Kate
    Lau, Chak S.
    Navarra, Sandra V.
    Louthrenoo, Worawit
    Lateef, Aisha
    Hamijoyo, Laniyati
    Wahono, Singgih
    Chen, Shun-Le
    Ou, Jinou
    Hoi, Alberta Y.
    Nikpour, Mandana
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S664 - S665
  • [24] LLDAS (LOW LUPUS DISEASE ACTIVITY STATE), LOW DISEASE ACTIVITY (LDA) AND REMISSION (ON- OR OFF-TREATMENT) PREVENT DAMAGE ACCRUAL IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PATIENTS IN A MULTINATIONAL MULTICENTER COHORT
    Ugarte-Gil, M. F.
    Hanly, J.
    Urowitz, M. B.
    Gordon, C.
    Bae, S. C.
    Romero-Diaz, J.
    Sanchez-Guerrero, J.
    Bernatsky, S.
    Clarke, A. E.
    Wallace, D. J.
    Isenberg, D.
    Rahman, A.
    Merrill, J. T.
    Fortin, P.
    Gladman, D. D.
    Bruce, I. N.
    Petri, M. A.
    Ginzler, E. M.
    Dooley, M. A.
    Ramsey-Goldman, R.
    Manzi, S.
    Jonsen, A.
    Van Vollenhoven, R.
    Aranow, C.
    Mackay, M.
    Ruiz-Irastorza, G.
    Lim, S. S.
    Inanc, M.
    Kalunian, K. C.
    Jacobsen, S.
    Peschken, C.
    Kamen, D. L.
    Askanase, A.
    Pons-Estel, B.
    Alarcon, G. S.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 177 - 178
  • [25] BASELINE FACTORS ASSOCIATED WITH LUPUS FLARES: A POST-HOC ANALYSIS OF PATIENTS WITH MODERATE TO SEVERE ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS ENROLLED IN A 48 WEEK PHASE II RANDOMIZED CLINICAL TRIAL
    Lindsay, L.
    Mao, H. A.
    Cheng, J. E.
    Chuo, C. Y.
    Jones, N.
    Cascino, M. D.
    Tuckwell, K.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 648 - 648
  • [26] Population pharmacokinetic analysis of sifalimumab from a clinical phase IIb trial in systemic lupus erythematosus patients
    Zheng, Bo
    Yu, Xiang-Qing
    Greth, Warren
    Robbie, Gabriel J.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 81 (05) : 918 - 928
  • [27] CAN THE SLE-DAS SUBSTITUTE BILAG TO MEASURE LUPUS DISEASE ACTIVITY IN CLINICAL TRIALS? POST-HOC ANALYSIS OF THE BLISS-76 TRIAL
    Jesus, D.
    Matos, A.
    Henriques, C.
    Doria, A.
    Ines, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 634 - 635
  • [28] OPTIMIZING A DEFINITION OF LUPUS LOW DISEASE ACTIVITY STATE (LDA) FOR DAILY CLINICAL PRACTICE: SLE-DAS LDA VS LLDAS
    Assuncao, H.
    Jesus, D.
    Da Silva, J. A. P.
    Ines, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 60 - 61
  • [29] Impaired hand function and performance in activities of daily living in systemic lupus erythematosus, even in patients achieving lupus low disease activity state (LLDAS)
    Keramiotou, Kyriaki
    Anagnostou, Christos
    Konstantonis, George
    Kataxaki, Evangelia
    Sfikakis, Petros P.
    Tektonidou, Maria G.
    RHEUMATOLOGY ADVANCES IN PRACTICE, 2021, 5 (02)
  • [30] DAPIROLIZUMAB PEGOL EFFICACY BY SUBGROUPS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A POST HOC ANALYSIS OF PHASE 2 CLINICAL TRIAL DATA
    Askanase, A.
    Stach, C.
    Brittain, C.
    Stojan, G.
    Furie, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 272 - 273
12345